EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... December 5, 2022 Feeding the Gut July 14, 2023 ‘Dance Moms’ Star Abby Lee Miller Opens Up About Her Cancer... April 19, 2019 Prize winning early detection research October 7, 2021 Load more HOT NEWS 6 Things That Helped Me Think Positively During Cancer: A Patient... Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... Immune interception represents an exciting opportunity to stop cancer in its... Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed...
